Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Tenax Therapeutics presented additional Phase 3 LEVEL trial results for TNX-103 (oral levosimendan) in patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). While the primary endpoint of 6-minute walk distance improvement did not achieve statistical significance in the overall population, prespecified subgroup analyses showed favorable results in patients with baseline 6MWD below 333 meters, including a 26.3-meter improvement in walk distance and a 47% reduction in NT-proBNP. The company plans to enrich the LEVEL-2 trial population based on these findings.